Information Provided By:
Fly News Breaks for February 12, 2018
AXGN
Feb 12, 2018 | 08:36 EDT
After traveling with management, Jefferies analyst Raj Denhoy says the AxoGen story "remains very compelling." While converting surgeons from the current accepted standard takes time, AxoGen's better technologies, growing body of clinical and economic evidence, and no real competition should keep its growth at least 40% for the next two years, and "likely much longer," Denhoy tells investors in a research note. He keeps a Buy rating on the shares with a $35 price target.
News For AXGN From the Last 2 Days
There are no results for your query AXGN